Keyword Analysis & Research: revolution medicines
Keyword Research: People who searched revolution medicines also searched
Search Results related to revolution medicines on Search Engine
-
Pipeline - Revolution Medicines
https://www.revmed.com/pipeline/
WEBRevolution Medicines is building a deep pipeline in support of its focus on the development and delivery of novel targeted therapies to patients with RAS-addicted cancers.
DA: 70 PA: 68 MOZ Rank: 71
-
Investor Relations | Revolution Medicines
https://ir.revmed.com/
WEBRevolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies.
DA: 34 PA: 71 MOZ Rank: 35
-
Revolution Medicines | LinkedIn
https://www.linkedin.com/company/revolution-medicines/
WEBREVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product …
DA: 22 PA: 73 MOZ Rank: 36
-
Revolution Medicines: An Expensive Shot At A Massive Market …
https://seekingalpha.com/article/4683402-revolution-medicines-stock-expensive-shot-massive-market-opportunity-hold
WEBApr 12, 2024 · Revolution Medicines raised $238 million via its 2020 IPO, and 4 years later has grown its share price by ~30%, bringing its market cap valuation to $6 billion. The company is pioneering a unique ...
DA: 46 PA: 7 MOZ Rank: 19
-
Revolution Medicines, Inc. to Acquire EQRx, Inc. in
https://www.globenewswire.com/news-release/2023/08/01/2715636/0/en/Revolution-Medicines-Inc-to-Acquire-EQRx-Inc-in-All-Stock-Transaction-to-Gain-More-Than-1-Billion-in-Additional-Capital.html
WEBAug 1, 2023 · REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (“Revolution Medicines” or the “Company”) (Nasdaq: RVMD), a clinical-stage oncology...
DA: 24 PA: 97 MOZ Rank: 15
-
Revolution Medicines Doses First Patient in Phase 1/1b Clinical …
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-doses-first-patient-phase-11b-clinical-0
WEBREDWOOD CITY, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-9805, an oral, covalent, mutant-selective KRAS G12D …
DA: 38 PA: 79 MOZ Rank: 97
-
Revolution Medicines Advances First RAS(ON) Inhibitor into …
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-advances-first-rason-inhibitor-clinic
WEBJun 28, 2022 · Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS (ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.
DA: 67 PA: 92 MOZ Rank: 6
-
Glue-based KRAS inhibitors make their debut cancer trial mark
https://www.nature.com/articles/d41573-023-00169-8
WEB23 October 2023. Glue-based KRAS inhibitors make their debut cancer trial mark. By. Asher Mullard. Revolution Medicines’ KRAS inhibitors RMC-6236 and RMC-6291 have notched up encouraging phase...
DA: 7 PA: 99 MOZ Rank: 12
-
About - Revolution Medicines
https://www.revmed.com/about/
WEBAbout - Revolution Medicines. We are Revolutionaries. At RevMed our mission is to revolutionize treatment for patients with RAS-addicted cancers through innovative, targeted medicines.
DA: 48 PA: 57 MOZ Rank: 100
